Termination Report. For each Licensed Product, MEDIMMUNE also agrees to make a written report to PDL within ninety (90) days after the date on which MEDIMMUNE, its Affiliates or sublicensees last sell that Licensed Product in the Territory stating in such report the same information required by quarterly reports for all such Licensed Products made, sold or otherwise disposed of which were not previously reported to PDL.
Appears in 4 contracts
Samples: Patent License Agreement (PDL Biopharma, Inc.), Patent License Agreement (PDL Biopharma, Inc.), Patent License Agreement (Medimmune Inc /De)
